GetTopicDetailResponse(id=c1d115e3632, topicName=rubraca, introduction=rubraca, content=null, image=null, comments=5, allHits=1118, url=https://h5.medsci.cn/topic?id=15736, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=73028, tagList=[TagDto(tagId=73028, tagName=rubraca)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1993303, encodeId=0336199330389, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, objectTitle=PARP 抑制劑 Rubraca (rucaparib)一線治療晚期卵巢癌，顯著延長(zhǎng)了PFS, objectType=article, longId=302295, objectId=5d50302295d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d50302295d1, replyNumber=0, likeNumber=0, createdTime=2023-02-25, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d50302295d1, moduleTitle=PARP 抑制劑 Rubraca (rucaparib)一線治療晚期卵巢癌，顯著延長(zhǎng)了PFS, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=5d50302295d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993302, encodeId=3b33199330231, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, objectTitle=Rubraca在美國(guó)獲批，成為獲批治療前列腺癌的PARP抑制劑, objectType=article, longId=194252, objectId=942519425263, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=942519425263, replyNumber=0, likeNumber=100, createdTime=2020-11-09, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=942519425263, moduleTitle=Rubraca在美國(guó)獲批，成為獲批治療前列腺癌的PARP抑制劑, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=942519425263)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993300, encodeId=3d9219933004c, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, objectTitle=晚期卵巢癌：Rubraca的III期ARIEL3研究的全新數(shù)據(jù), objectType=article, longId=166644, objectId=25351666441e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25351666441e, replyNumber=0, likeNumber=84, createdTime=2019-07-21, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25351666441e, moduleTitle=晚期卵巢癌：Rubraca的III期ARIEL3研究的全新數(shù)據(jù), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=25351666441e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993301, encodeId=5a36199330179, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, objectTitle=Clovis的Rubraca超越了多個(gè)PARP抑制劑競(jìng)爭(zhēng)對(duì)手，在前列腺癌領(lǐng)域獲得FDA的優(yōu)先審查, objectType=article, longId=186457, objectId=94c818645e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94c818645e5b, replyNumber=0, likeNumber=107, createdTime=2020-10-03, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94c818645e5b, moduleTitle=Clovis的Rubraca超越了多個(gè)PARP抑制劑競(jìng)爭(zhēng)對(duì)手，在前列腺癌領(lǐng)域獲得FDA的優(yōu)先審查, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=94c818645e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993299, encodeId=7ee919932996b, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, objectTitle=Clovis Oncology宣布?xì)W洲委員會(huì)批準(zhǔn)Rubraca用于復(fù)發(fā)性卵巢癌的維持治療, objectType=article, longId=158910, objectId=54ad1589109b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54ad1589109b, replyNumber=0, likeNumber=74, createdTime=2019-11-14, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54ad1589109b, moduleTitle=Clovis Oncology宣布?xì)W洲委員會(huì)批準(zhǔn)Rubraca用于復(fù)發(fā)性卵巢癌的維持治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=54ad1589109b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
